What You Should Know
- The Milestone: AliveCor, a global leader in AI-powered cardiology, has secured a CE Mark (Conformité Européenne) for its Kardia 12L electrocardiogram (ECG) system, allowing it to be distributed across the European Economic Area.
- The Hardware Shift: The Kardia 12L effectively replaces the traditional, bulky 10-electrode ECG cart. It utilizes a unique single-cable, five-electrode design, runs on batteries, and weighs just 0.13 kg (0.3 lbs).
- The AI Engine: The device is powered by the KAI 12L AI algorithm. Using just the reduced leadset, the AI is cleared to detect 35 cardiac determinations, including 14 arrhythmias and 21 morphologies. Crucially, this includes life-threatening conditions like acute myocardial infarction (heart attacks) and cardiac ischemia.
- The Clinical Workflow: Because the hardware is simplified to five electrodes, patients do not need to fully disrobe during a reading. Research indicates this design yields a nearly 30% reduction in ECG acquisition time compared to standard 12-lead setups.
- The Rollout: Following its U.S. launch in June 2024, the CE Mark clears the way for AliveCor to immediately deploy the technology to healthcare providers in France, Germany, Italy, Spain, and the United Kingdom, with additional countries following shortly.
A New Standard for Point-of-Care Diagnostics
The Kardia 12L system is designed to replace bulky, traditional ECG carts with a pocket-sized, battery-operated device weighing just 0.13 kg (0.3 lbs). Unlike standard setups that require 10 electrodes and significant patient disrobing, the Kardia 12L uses a simplified five-electrode, single-cable design.
Key advantages of the system include:
- Rapid Acquisition: Clinical research has shown a nearly 30% reduction in ECG acquisition time compared to traditional setups.
- Diagnostic Depth: Powered by KAI™ 12L AI, the system can detect 35 cardiac determinations, including 14 arrhythmias and 21 morphologies.
- Life-Saving Detection: The AI is specifically cleared to identify acute myocardial infarction (MI) and common types of cardiac ischemia in real time.
Expanding Global Access
Since its U.S. FDA clearance in June 2024, the Kardia 12L has already been adopted in India, Australia, Canada, and several other nations. To date, the system has identified over 4,000 instances of MI and ischemia globally.
In Europe, the launch aligns with the EU Cardiovascular Health Plan, which prioritizes early detection and prevention of cardiovascular diseases—the leading cause of mortality in the region.
Availability
The Kardia 12L will initially be available to healthcare providers in the following countries:
- France
- Germany
- Italy
- Spain
- United Kingdom
Expansion into additional European countries is expected to follow shortly. While the device is highly portable, it is intended strictly for use by healthcare professionals in settings ranging from hospitals and urgent care centers to pharmacies and rural clinics.
“Our priority is to get this life-saving technology into the hands of as many clinicians as possible, especially in settings where traditional, bulky ECG carts simply aren’t practical,” said Simona Esposito, Senior Vice President of Sales, Global Markets at AliveCor.
